Last reviewed 2026-04-23 · How we verify

PL2200 Aspirin Capsules

PL2200 is a modified-release aspirin formulation designed to reduce gastrointestinal irritation while maintaining antiplatelet efficacy.

PL2200 is a modified-release aspirin formulation designed to reduce gastrointestinal irritation while maintaining antiplatelet efficacy. Used for Cardiovascular event prevention in patients at risk for aspirin-related gastrointestinal complications, Secondary prevention of myocardial infarction and stroke.

At a glance

Mechanism of action

PL2200 uses PLx Pharma's proprietary Phospholipid Delivery System (PDS) to coat aspirin with a protective phospholipid layer, which reduces direct contact with the gastric mucosa and decreases GI side effects. The formulation allows aspirin to be absorbed in the small intestine while maintaining its antiplatelet mechanism of action through irreversible cyclooxygenase (COX) inhibition.

Approved indications

• Cardiovascular event prevention in patients at risk for aspirin-related gastrointestinal complications
• Secondary prevention of myocardial infarction and stroke

Common side effects

• Gastrointestinal bleeding
• Dyspepsia
• Nausea

Key clinical trials

• Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated and Immediate Release Aspirin in Diabetic Patients (PHASE3)
• Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated Aspirin in Diabetic Patients (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• PL2200 Aspirin Capsules CI brief — competitive landscape report
• PL2200 Aspirin Capsules updates RSS · CI watch RSS
• PLx Pharma portfolio CI